Some human tumor cell lines are able to prevent chloroethylnitrosourea-ind~ced DNA-interStrand crosslinks by removing O -chloroethyl DNA monoadducts before cross,inks can form. The same cell lines can ~epair 0 -methyl-guanine adducts by guanine-O -~ethyl-transferase an~ were designated as Mer (methylation repair ). Methylating agents like MNNG or MNU are able to inactivate this repair system followed by an increase in chloroethylnitrosourea-induced DNA intersSrand crosslinks and in vitro cytotoxicity in Mer tumor cell lines. With regard to the potential benefit of such combinations for the treatment of human tumors knowledge of whole animal and organ toxicity is indispensible. We determined the combination toxicity index of MNU plus BCNU according to a method proposed by Skipper. The sums of the decimal fractions of the LDInS of both agents were opposed to the observed 9 ortality. The LDl0(sum) was calculated by probit analysis. Altogether 14 different combinations of both agents were investigated. The results revealed a combination toxicity index of 0.32, the lowest value reported so far for the combination of 2 cytostatic drugs. The main targets of toxicity were the intestinal ~ract and the bone marrow. 
IN
The culture of human tumor cells in a soft-agar colonyforming assay ("human tumor stem cell assay") has been suggested as an in vitro method to predict the clinical response to chemotherapeutic agents. We performed the assay using tumor samples from 74 patients. The primary tumors were as follows: breast (42), ovary (19), cervix (2), FalloDian tubes (I), endometrium (I), and vulva (I).
Tumor samples were mechanically and enzymatically disaggregated and filtered through meshes with pore sizes down to 60 ~m. We were unable to prepare one pure single cell suspension. Cells were plated in a bilayer soft agar system containing one of several cytotoxic drugs. Cell groups with a minimum diameter of 100 Hm were scored after 18 to 21 days. In vitro sensitivity was defined as a 50% or more decrease in the number of colonies. Only cell suspensions that were cytologically positive or suspect were able to grow in soft agar. Of the 74 sammles processed, only 39 gave a cell yield sufficient for plating. According to our criteria of evaluability, only 14% (10/74) of samples were considered evaluable.
Patients' treatment was independent of in vitro results. Prospective correlations of in vitro results with clLnical outcome were feasible in only 3 of the 10 evaluable samples and were correct in 2. We draw the following conclusions: (I) due to the low rate of evaluable samples, the assay has only limited value at our institution, Cultures were incubated at 37~ in 7,5 % CO o 9 ALP was added at concentrations of 7, 2, 4~ 8 and 76 ug/ml. The tumor samples revealed individual dose response curves. 8 out of 22 tumor probes showed a reduction of colony formation to less than 20% of control growth at a concentration of 76 ug/ ml (2 colorectal tumors, 2 malignant melanomas, 1 ovarian carcinoma~ ~ squamous cell carcinoma, 7 adenocarcinoma, 7 small cell carcinoma of the lung). In two cases no reduction of colony formation was observed. The other tumors yielded a colony reduction between 20 and 60% of the controls. We conclude that the ALP BM 41 4%0 acts cytotoxic on human clonogenic tumor cells in vitro. This new class of tumor agents deserves further investigations. Medizinische Klinik und Frauenklinik der Albert-Ludwigs-UniversitNt Freiburg, Hugstetterstr.
55, 7800 Freiburg.
